NutritionDIETMICRONCT07672691
Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers
A study testing Ketogenic Diet (KD) and Vegetarian Diet (VD) in people with Nutrition and Ketogenic Diet, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 2 sites in Poland.
Trial summary
This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Nutrition, Ketogenic Diet, Gene Expression
- What is being tested?
- Ketogenic Diet (KD) and Vegetarian Diet (VD)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 2 sitesPoland
- Study dates
- 2 Sep 2024to 30 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- In addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:
- BMI not exceeding 40kg/m²
- Habitual mixed diet prior to study enrollment
- Normal blood pressure
Who cannot join
- Poprawiłem już Exclusion Criteria w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:
- Exclusion Criteria:
- Use of medications regulating glucose levels (e.g., metformin) or blood lipids (e.g., statins)
- Hypertension or pharmacological treatment for hypertension
- Diagnosed gastrointestinal disorders, including:
- Gastric and duodenal ulcers
Show all 20Show fewer
- Irritable bowel syndrome (IBS)
- Ulcerative colitis
- Celiac disease
- Chronic use of medications such as:
- Mesalazine
- Corticosteroids
- Statins
- Proton pump inhibitors (PPI)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Anticonceptional medications
- Any supplements
- Alcohol consumption > 2 times/week with > 15 g alcohol per occasion (approximately 15 g alcohol = 330 mL beer, 150 mL dry red wine, or 50 mL vodka)
- Smoking cigarettes
- Following a ketogenic diet or vegetarian diet within 1 month prior to study enrollment
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Małgorzata Magdalena Michalczyk, Assistante professor contact
Poland2 sites, 2 recruiting
- Recruiting
Jaggielonian University
Krakow
Wojciech Branicki, Profesor, 605576336, wojciech.branicki@uj.edu.pl
- Recruiting
Pomeranian Medical University
Szczecin
Ewelina Pośpiech, Assistance professor, Pomeranian Medical, ewelina.pospiech@pum.edu.pl
Grzegorz Zydek, Phd, 504332664, g.zydek@awf.katowice.pl
About this study
Official title: Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.
This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.
Participants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.
Read more
The study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.
By comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.
Read the detailed description
This 12-week randomized controlled trial will evaluate the effects of diets differing in macronutrient composition on gut microbiota, intestinal inflammation markers, gene expression profiles, and blood biochemical parameters. All participants will undergo comprehensive measurements and laboratory assessments at four time points: before the study begins (baseline), after 4 weeks, after 8 weeks, and at 12 weeks (study completion).
At each assessment point (baseline, 4, 8, and 12 weeks), all participants will visit the laboratory in a fasting state and undergo the following measurements:
- Body mass and body composition assessment
- Transcriptomic analysis
- Cellular metabolism studies
- Biochemical blood parameters
- Gut microbiome analysis
Additionally, participants in the ketogenic diet (KD) group will measure blood ketone levels once weekly throughout the entire study period to monitor dietary adherence. All participants will complete questionnaires assessing stress levels and appetite before, during, and after the study intervention.
Body Mass and Body Composition Measurement
Body composition will be measured on an empty stomach in the supine position using Dual-Energy X-ray Absorptiometry (DEXA). This method utilizes the phenomenon of ionizing radiation beam attenuation as it passes through tissues of different densities. The difference in absorption of two energy levels (43 and 110 keV) by soft tissue and bone tissue enables assessment of both bone mineral density (BMD) and fat tissue content. DEXA is characterized by high accuracy and reproducibility. The examination lasts up to a few minutes, and radiation exposure is minimal. DEXA can be performed during hormonal therapy, hormonal disorders, dietary restrictions, or physical exercise.
Transcriptomic Studies, Cellular Metabolism, Gene Polymorphism, and Biochemical Analyses
For transcriptomic, cellular metabolism, and biochemical studies, 10 mL of venous blood will be collected from the antecubital vein. Simultaneously, at the beginning of the study only, an oral swab will be collected from each participant for gene polymorphism analysis.
Blood and oral swabs will be collected by a nurse at the Functional Examination Laboratory of the Academy of Physical Education in Katowice.
Transcriptomic Analysis
Transcriptomic studies will be conducted in mononuclear blood cells (PBMC) using microarrays. PBMCs will be obtained by centrifuging whole blood in a Ficoll gradient. To obtain sufficient cell quantity, 8 mL of blood will be collected into two 4 mL tubes. The plasma obtained after centrifugation will be stored for biochemical assays and isolation of free-circulating RNA molecules (for potential subsequent studies of selected molecules based on transcriptomic results).
PBMCs will be counted using an automatic cell counter (TC20 cell counter, Biorad) and divided into two parts. From 8 mL of blood, 4-10 mL of live mononuclear cells are obtained. One million cells will be cryopreserved in appropriate medium for subsequent cellular metabolism studies (Seahorse, Agilent). This cell quantity enables performance of each of three possible tests (ATP rate assay, glycolytic rate, mito stress), with test selection based on transcriptomic study results.
Remaining cells will immediately undergo total RNA isolation using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA concentration will be assessed using a Qubit4 fluorometer (Thermo), and integrity using a Bioanalyzer 2100 (Agilent) with RNA 6000 Nano Assay kits (Agilent). Microarray studies require at least 4 μL RNA at 67 ng/μL concentration with RIN coefficient ≥7. From the planned blood quantity, we obtain 200-400 ng/μL in 30 μL volume.
Gene expression will be evaluated using SurePrint G3 Human Gene Expression 8x60K v2 Microarray Kits. The procedure will follow the manufacturer's protocol and include: cDNA synthesis, cRNA synthesis and amplification, sample preparation for hybridization, hybridization (17 h, 65°C), washing, scanning (SureScan, Agilent), and image analysis (Feature Extraction software, Agilent). Results will be analyzed using GeneSpring software.
Cellular Metabolism Analysis
Cellular metabolism studies (ATP-rate assay, Cell Mito Stress, Glycolytic Rate) will be conducted in previously cryopreserved PBMCs using the Seahorse device (Agilent). After thawing, the number of live cells will be counted, then cells will be seeded onto poly-D-lysine-coated measurement plates. Analyses will be performed according to the manufacturer's protocol.
Gene Polymorphism Analysis Related to Macronutrient Metabolism
At study initiation, genetic material will be collected from each participant as an oral swab. This material will be used to analyze polymorphism of genes FTO, GATA3, PPRG2, TCF7L2, ADRB2, APOA2, APOA, and FABP2, associated with protein, fat, and carbohydrate metabolism. The analysis will be performed at Genomix4Life S.r.l. laboratory, a spin-off of the University of Salerno in Italy.
Biochemical Studies
From the 10 mL of blood collected for all studies, 2 mL will be designated for biochemical analyses. The following parameters will be measured:
- Triacylglycerol (TG, mg/dL)
- LDL cholesterol (LDL-C, mg/dL)
- HDL cholesterol (HDL-C, mg/dL)
- Total cholesterol (tCh, mg/dL)
- Omega index
- Glucose (Gl, mg/dL)
- Glycated hemoglobin (HbA1c, %)
- Insulin (I, IU/mL)
- Testosterone (nmol/L)
- Cortisol (μg/dL)
- Inflammatory protein (CRP, mg/L)
- β-hydroxybutyrate (β-HGB, mmol/L)
Additionally, the HOMA-IR index will be calculated using the formula: fasting insulin concentration × fasting glucose concentration / 22.5.
1 mL of blood will be used for serum determination of factors playing essential roles in appetite control: grelin, cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), leptin, and peptide Y-Y (PYY). These determinations will be performed using ELISA method. Diagnostic kits from Randox (UK), Roche Diagnostic, Diagnostic System Laboratories (Webster, TX, USA), and Beckman Coulter, R\&D, Biotechne will be used. The Omega index will be measured using gas chromatography GC-FID with flame ionization detection.
Ketone Body Measurement as Ketosis Indicator
For ketogenic diet control, participants in the KD group will measure blood ketone levels once weekly, in the morning before breakfast, by collecting 1 drop of blood from the finger using a glucose meter with ketone measurement function (Optimum Xido or Optimum Xido Neo, USA Abbott Laboratories, Chicago, Illinois) or using commercially available urinary ketone test strips (Ketur-Test, Roche Diagnostics, Basel, Switzerland). Results will be discussed with a dietitian during visits at 4, 8, and 12 weeks.
Stool Sample Analysis
On the day of laboratory visit for body mass and composition measurements, participants will deliver biological materials (approximately 10 g of stool) for gut microbiota composition analysis.
Stool microflora analysis will enable qualitative and quantitative assessment of selected bacterial types and species in the gastrointestinal tract. For quantitative analysis of bacteria, yeasts, and molds, a specified stool weight is placed in appropriate volume of liquid culture medium and subjected to careful homogenization (using BagMixer® S\&SW) to achieve homogeneous suspension. From the suspension, a series of 10-fold dilutions is performed, then plated on selective-differential microbiological media.
Bacterial, yeast, and mold cultures are conducted under appropriate conditions:
- Aerobic bacteria: incubation 24 hours, temperature 37°C, aerobic conditions
- Anaerobic bacteria: incubation 48-72 hours, temperature 37°C, anaerobic conditions
- Campylobacter spp.: incubation 72 hours, temperature 42°C, microaerophilic conditions
- Yeast-like fungi and molds: incubation 48 hours, temperature 37°C, aerobic conditions
After specified incubation time, cultures undergo microbiological diagnostics using culture methods, biochemical methods, and MALDI TOF mass spectrometry. For yeast-like fungi and molds, mycological diagnostics are performed using chromogenic media.
The following microorganisms will be evaluated:
- Anaerobic bacteria: Bacteroides spp. and Bifidobacterium spp., Lactobacillus spp. (including hydrogen peroxide-producing strains), proteolytic microflora bacteria: Clostridium spp. (including Clostridium difficile)
- Proteolytic microflora bacteria: Campylobacter spp. Aerobic bacteria: Enterococcus spp., Gram-negative E. coli
- Proteolytic microflora bacteria: potentially pathogenic E. coli biovar form, Providencia spp., Salmonella spp., Shigella spp., Yersinia spp., Hafnia alvei, Enterobacteriaceae family (Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus spp., Morganella spp., Serratia spp.), and Pseudomonas spp.
- Total bacterial count: Bacillus spp.
- Yeast-like fungi: Candida albicans, Candida non-albicans, and mold fungi
Additionally, a sample for qualitative analysis of indicator bacteria using PCR method will be extracted. This assesses presence of enterocyte-feeding bacteria: Akkermansia muciniphila and Fecalibacterium prausnitzii.
In stool samples, inflammatory markers will also be measured: calprotectin, eosinophilic protein X, and alpha-1-antitrypsin.
- Conditions
- Nutrition, Ketogenic Diet, Gene Expression, Diet
- Being tested
- Ketogenic Diet (KD), Vegetarian Diet (VD), Control Diet (CD)
- Keywords
- ketogenic diet, gene expression, transcriptomics, biochemical parameters, stool microbiome, ketone bodies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketogenic Diet (KD)Other
Participants in the Ketogenic Diet Group (KD) will follow a strict ketogenic diet for 12 weeks. The ketogenic diet is characterized by:
Fat intake: Approximately 70-80% of total daily energy Carbohydrate intake: Approximately 5-10% of total daily energy (typically <50 g carbohydrates per day) Moderate protein intake: Approximately 15-20% of total daily energy
Dietary Guidelines:
Allowed foods: Fatty meats, fish, eggs, full-fat dairy products, butter, oils (olive oil, coconut oil, avocado oil), nuts, seeds, low-carbohydrate vegetables (e.g., leafy greens, broccoli, cauliflower), avocados Restricted foods: All grains (bread, pasta, rice, cereals), high-carbohydrate fruits (bananas, apples, oranges), starchy vegetables (potatoes, corn), legumes, sugar-sweetened foods and beverages, most processed foods Blood ketone levels will be measured once weekly by participants (morning, before breakfast) using a ketone meter (Optimum Xido) Duration: 12 weeks
Vegetarian Diet (VD)Other
Participants in the Vegetarin Diet Group (VD) will follow a plant-based vegetarian diet for 12 weeks. The vegetarin diet excludes all animal products and is characterized by:
Macronutrient composition: Balanced intake of carbohydrates, proteins, and fats from plant sources
Primary food sources: Vegetables, fruits, legumes (beans, lentils, peas), nuts, seeds, whole grains, plant-based oils
Dietary Guidelines:
Allowed foods: All vegetables, fruits, legumes, nuts, seeds, whole grains (rice, quinoa, oats, wheat), plant-based milks, tofu, tempeh, plant-based oils, avocados Restricted foods: All animal products including meat, poultry, fish, eggs, dairy products, honey, and any food containing animal-derived ingredients Dietary adherence will be monitored through regular food diaries and nutritional counseling sessions
Participants will receive guidance on adequate protein intake, vitamin B12, iron, calcium, and omega-3 fatty acid supplementation if needed Duration: 12 weeks
Control Diet (CD)Other
Participants in the Control Diet Group (CD) will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications for 12 weeks.
Diet type: Habitual mixed diet (includes both plant and animal products)
Macronutrient composition: No modifications; participants maintain their usual dietary intake No dietary restrictions or instructions: Participants are not instructed to change their eating patterns
Monitoring:
Dietary intake will be documented through regular food diaries Participants will attend visits with a dietitian at 4, 8, and 12 weeks for monitoring purposes only (no dietary changes instructed) Duration: 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Ketogenic diet | Experimental | Participants in this arm will follow a ketogenic diet characterized by high fat, very low carbohydrate, and moderate protein intake throughout the 12-week intervention period. Receives: Other: Ketogenic Diet (KD) |
| Vegetarian Diet Group | Experimental | Participants in this arm will follow a plant-based vegan diet excluding all animal products throughout the 12-week intervention period. Receives: Other: Vegetarian Diet (VD) |
| Control Diet Group (CD) | Placebo comparator | Participants in this arm will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications throughout the 12-week study period. Receives: Other: Control Diet (CD) |
What is being measured
The primary outcome is the main question the study is designed to answer.
β-hydroxybutyrate
mmol/L
Measured: 12 weeks
Insulin
IU/mL
Measured: 12 weeks
Glucose
mg/dL
Measured: 12 weeks
Omega index
Measured: 12 weeks
HDL cholesterol
mg/dL
Measured: 12 weeks
LDL cholesterol
mg/dL
Measured: 12 weeks
Triacylglycerol
mg/dL
Measured: 12 weeks
Grelin
ng/mL
Measured: 12 weeks
cholecystokinin
pg/mL
Measured: 12 weeks
glucagon-like peptide-1
pg/mL
Measured: 12 weeks
leptin
ng/mL
Measured: 12 weeks
peptide YY
pg/mL
Measured: 12 weeks
gut microbiome
CFU/g
Measured: 12 weeks
Transcriptomic
log 2fold change
Measured: 12 weeks
Gene Polymorphism
allel variance
Measured: 12 weeks
Total cholesterol
mg/dL
Measured: 12 weeks
HbA1c
Measured: 12 weeks
Testosterone
nmol/L
Measured: 12 weeks
Cortisol
μg/dL
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start2 Sep 2024
- Primary completion3 Sep 2024
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Jerzy Kukuczka Academy of Physical Education in Katowice
- Sponsor type
- University, hospital or other
- Collaborators
- Jagiellonian University, Pomeranian Medical University Szczecin
- Responsible party
- Principal investigator, Małgorzata Magdalena Michalczyk, The Jerzy Kukuczka Academy of Physical Education in Katowice
- Investigators
- Małgorzata M Michalczyk, Assistante professor, Principal investigator, Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07672691
- Sponsor's protocol ID
- KB- 2/2021
- Other IDs
- Institute of Sport Science
- Acronym
- DIETMICRO
- Status last verified
- Jul 2026
- First submitted
- 17 Jun 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.
- ClinicalTrials.gov ID
- NCT07672691
- Acronym / sponsor ID
- DIETMICRO / KB- 2/2021
- Conditions
- Nutrition, Ketogenic Diet, Gene Expression, Diet
- Keywords
- ketogenic diet, gene expression, transcriptomics, biochemical parameters, stool microbiome, ketone bodies
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- The Jerzy Kukuczka Academy of Physical Education in KatowiceUniversity, hospital or other
- Collaborators
- Jagiellonian University, Pomeranian Medical University Szczecin
- Study start
- 2 Sep 2024 (actual)
- Primary completion
- 3 Sep 2024 (actual)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.
Participants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.
The study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.
By comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.
Detailed description
This 12-week randomized controlled trial will evaluate the effects of diets differing in macronutrient composition on gut microbiota, intestinal inflammation markers, gene expression profiles, and blood biochemical parameters. All participants will undergo comprehensive measurements and laboratory assessments at four time points: before the study begins (baseline), after 4 weeks, after 8 weeks, and at 12 weeks (study completion).
At each assessment point (baseline, 4, 8, and 12 weeks), all participants will visit the laboratory in a fasting state and undergo the following measurements:
- Body mass and body composition assessment
- Transcriptomic analysis
- Cellular metabolism studies
- Biochemical blood parameters
- Gut microbiome analysis
Additionally, participants in the ketogenic diet (KD) group will measure blood ketone levels once weekly throughout the entire study period to monitor dietary adherence. All participants will complete questionnaires assessing stress levels and appetite before, during, and after the study intervention.
Body Mass and Body Composition Measurement
Body composition will be measured on an empty stomach in the supine position using Dual-Energy X-ray Absorptiometry (DEXA). This method utilizes the phenomenon of ionizing radiation beam attenuation as it passes through tissues of different densities. The difference in absorption of two energy levels (43 and 110 keV) by soft tissue and bone tissue enables assessment of both bone mineral density (BMD) and fat tissue content. DEXA is characterized by high accuracy and reproducibility. The examination lasts up to a few minutes, and radiation exposure is minimal. DEXA can be performed during hormonal therapy, hormonal disorders, dietary restrictions, or physical exercise.
Transcriptomic Studies, Cellular Metabolism, Gene Polymorphism, and Biochemical Analyses
For transcriptomic, cellular metabolism, and biochemical studies, 10 mL of venous blood will be collected from the antecubital vein. Simultaneously, at the beginning of the study only, an oral swab will be collected from each participant for gene polymorphism analysis.
Blood and oral swabs will be collected by a nurse at the Functional Examination Laboratory of the Academy of Physical Education in Katowice.
Transcriptomic Analysis
Transcriptomic studies will be conducted in mononuclear blood cells (PBMC) using microarrays. PBMCs will be obtained by centrifuging whole blood in a Ficoll gradient. To obtain sufficient cell quantity, 8 mL of blood will be collected into two 4 mL tubes. The plasma obtained after centrifugation will be stored for biochemical assays and isolation of free-circulating RNA molecules (for potential subsequent studies of selected molecules based on transcriptomic results).
PBMCs will be counted using an automatic cell counter (TC20 cell counter, Biorad) and divided into two parts. From 8 mL of blood, 4-10 mL of live mononuclear cells are obtained. One million cells will be cryopreserved in appropriate medium for subsequent cellular metabolism studies (Seahorse, Agilent). This cell quantity enables performance of each of three possible tests (ATP rate assay, glycolytic rate, mito stress), with test selection based on transcriptomic study results.
Remaining cells will immediately undergo total RNA isolation using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA concentration will be assessed using a Qubit4 fluorometer (Thermo), and integrity using a Bioanalyzer 2100 (Agilent) with RNA 6000 Nano Assay kits (Agilent). Microarray studies require at least 4 μL RNA at 67 ng/μL concentration with RIN coefficient ≥7. From the planned blood quantity, we obtain 200-400 ng/μL in 30 μL volume.
Gene expression will be evaluated using SurePrint G3 Human Gene Expression 8x60K v2 Microarray Kits. The procedure will follow the manufacturer's protocol and include: cDNA synthesis, cRNA synthesis and amplification, sample preparation for hybridization, hybridization (17 h, 65°C), washing, scanning (SureScan, Agilent), and image analysis (Feature Extraction software, Agilent). Results will be analyzed using GeneSpring software.
Cellular Metabolism Analysis
Cellular metabolism studies (ATP-rate assay, Cell Mito Stress, Glycolytic Rate) will be conducted in previously cryopreserved PBMCs using the Seahorse device (Agilent). After thawing, the number of live cells will be counted, then cells will be seeded onto poly-D-lysine-coated measurement plates. Analyses will be performed according to the manufacturer's protocol.
Gene Polymorphism Analysis Related to Macronutrient Metabolism
At study initiation, genetic material will be collected from each participant as an oral swab. This material will be used to analyze polymorphism of genes FTO, GATA3, PPRG2, TCF7L2, ADRB2, APOA2, APOA, and FABP2, associated with protein, fat, and carbohydrate metabolism. The analysis will be performed at Genomix4Life S.r.l. laboratory, a spin-off of the University of Salerno in Italy.
Biochemical Studies
From the 10 mL of blood collected for all studies, 2 mL will be designated for biochemical analyses. The following parameters will be measured:
- Triacylglycerol (TG, mg/dL)
- LDL cholesterol (LDL-C, mg/dL)
- HDL cholesterol (HDL-C, mg/dL)
- Total cholesterol (tCh, mg/dL)
- Omega index
- Glucose (Gl, mg/dL)
- Glycated hemoglobin (HbA1c, %)
- Insulin (I, IU/mL)
- Testosterone (nmol/L)
- Cortisol (μg/dL)
- Inflammatory protein (CRP, mg/L)
- β-hydroxybutyrate (β-HGB, mmol/L)
Additionally, the HOMA-IR index will be calculated using the formula: fasting insulin concentration × fasting glucose concentration / 22.5.
1 mL of blood will be used for serum determination of factors playing essential roles in appetite control: grelin, cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), leptin, and peptide Y-Y (PYY). These determinations will be performed using ELISA method. Diagnostic kits from Randox (UK), Roche Diagnostic, Diagnostic System Laboratories (Webster, TX, USA), and Beckman Coulter, R\&D, Biotechne will be used. The Omega index will be measured using gas chromatography GC-FID with flame ionization detection.
Ketone Body Measurement as Ketosis Indicator
For ketogenic diet control, participants in the KD group will measure blood ketone levels once weekly, in the morning before breakfast, by collecting 1 drop of blood from the finger using a glucose meter with ketone measurement function (Optimum Xido or Optimum Xido Neo, USA Abbott Laboratories, Chicago, Illinois) or using commercially available urinary ketone test strips (Ketur-Test, Roche Diagnostics, Basel, Switzerland). Results will be discussed with a dietitian during visits at 4, 8, and 12 weeks.
Stool Sample Analysis
On the day of laboratory visit for body mass and composition measurements, participants will deliver biological materials (approximately 10 g of stool) for gut microbiota composition analysis.
Stool microflora analysis will enable qualitative and quantitative assessment of selected bacterial types and species in the gastrointestinal tract. For quantitative analysis of bacteria, yeasts, and molds, a specified stool weight is placed in appropriate volume of liquid culture medium and subjected to careful homogenization (using BagMixer® S\&SW) to achieve homogeneous suspension. From the suspension, a series of 10-fold dilutions is performed, then plated on selective-differential microbiological media.
Bacterial, yeast, and mold cultures are conducted under appropriate conditions:
- Aerobic bacteria: incubation 24 hours, temperature 37°C, aerobic conditions
- Anaerobic bacteria: incubation 48-72 hours, temperature 37°C, anaerobic conditions
- Campylobacter spp.: incubation 72 hours, temperature 42°C, microaerophilic conditions
- Yeast-like fungi and molds: incubation 48 hours, temperature 37°C, aerobic conditions
After specified incubation time, cultures undergo microbiological diagnostics using culture methods, biochemical methods, and MALDI TOF mass spectrometry. For yeast-like fungi and molds, mycological diagnostics are performed using chromogenic media.
The following microorganisms will be evaluated:
- Anaerobic bacteria: Bacteroides spp. and Bifidobacterium spp., Lactobacillus spp. (including hydrogen peroxide-producing strains), proteolytic microflora bacteria: Clostridium spp. (including Clostridium difficile)
- Proteolytic microflora bacteria: Campylobacter spp. Aerobic bacteria: Enterococcus spp., Gram-negative E. coli
- Proteolytic microflora bacteria: potentially pathogenic E. coli biovar form, Providencia spp., Salmonella spp., Shigella spp., Yersinia spp., Hafnia alvei, Enterobacteriaceae family (Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus spp., Morganella spp., Serratia spp.), and Pseudomonas spp.
- Total bacterial count: Bacillus spp.
- Yeast-like fungi: Candida albicans, Candida non-albicans, and mold fungi
Additionally, a sample for qualitative analysis of indicator bacteria using PCR method will be extracted. This assesses presence of enterocyte-feeding bacteria: Akkermansia muciniphila and Fecalibacterium prausnitzii.
In stool samples, inflammatory markers will also be measured: calprotectin, eosinophilic protein X, and alpha-1-antitrypsin.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Ketogenic diet | Experimental | Other: Ketogenic Diet (KD)Participants in this arm will follow a ketogenic diet characterized by high fat, very low carbohydrate, and moderate protein intake throughout the 12-week intervention period. |
| Vegetarian Diet Group | Experimental | Other: Vegetarian Diet (VD)Participants in this arm will follow a plant-based vegan diet excluding all animal products throughout the 12-week intervention period. |
| Control Diet Group (CD) | Placebo comparator | Other: Control Diet (CD)Participants in this arm will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications throughout the 12-week study period. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- In addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:
- BMI not exceeding 40kg/m²
- Habitual mixed diet prior to study enrollment
- Normal blood pressure
Key exclusion criteria (20 listed)
- Poprawiłem już Exclusion Criteria w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:
- Exclusion Criteria:
- Use of medications regulating glucose levels (e.g., metformin) or blood lipids (e.g., statins)
- Hypertension or pharmacological treatment for hypertension
- Diagnosed gastrointestinal disorders, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketogenic Diet (KD)Participants in the Ketogenic Diet Group (KD) will follow a strict ketogenic diet for 12 weeks. The ketogenic diet is characterized by: Fat intake: Approximately 70-80% of total daily energy Carbohydrate intake: Approximately 5-10% of total daily energy (typically <50 g carbohydrates per day) Moderate protein intake: Approximately 15-20% of total daily energy Dietary Guidelines: Allowed foods: Fatty meats, fish, eggs, full-fat dairy products, butter, oils (olive oil, coconut oil, avocado oil), nuts, seeds, low-carbohydrate vegetables (e.g., leafy greens, broccoli, cauliflower), avocados Restricted foods: All grains (bread, pasta, rice, cereals), high-carbohydrate fruits (bananas, apples, oranges), starchy vegetables (potatoes, corn), legumes, sugar-sweetened foods and beverages, most processed foods Blood ketone levels will be measured once weekly by participants (morning, before breakfast) using a ketone meter (Optimum Xido) Duration: 12 weeks | Other | Ketogenic diet |
| Vegetarian Diet (VD)Participants in the Vegetarin Diet Group (VD) will follow a plant-based vegetarian diet for 12 weeks. The vegetarin diet excludes all animal products and is characterized by: Macronutrient composition: Balanced intake of carbohydrates, proteins, and fats from plant sources Primary food sources: Vegetables, fruits, legumes (beans, lentils, peas), nuts, seeds, whole grains, plant-based oils Dietary Guidelines: Allowed foods: All vegetables, fruits, legumes, nuts, seeds, whole grains (rice, quinoa, oats, wheat), plant-based milks, tofu, tempeh, plant-based oils, avocados Restricted foods: All animal products including meat, poultry, fish, eggs, dairy products, honey, and any food containing animal-derived ingredients Dietary adherence will be monitored through regular food diaries and nutritional counseling sessions Participants will receive guidance on adequate protein intake, vitamin B12, iron, calcium, and omega-3 fatty acid supplementation if needed Duration: 12 weeks | Other | Vegetarian Diet Group |
| Control Diet (CD)Participants in the Control Diet Group (CD) will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications for 12 weeks. Diet type: Habitual mixed diet (includes both plant and animal products) Macronutrient composition: No modifications; participants maintain their usual dietary intake No dietary restrictions or instructions: Participants are not instructed to change their eating patterns Monitoring: Dietary intake will be documented through regular food diaries Participants will attend visits with a dietitian at 4, 8, and 12 weeks for monitoring purposes only (no dietary changes instructed) Duration: 12 weeks | Other | Control Diet Group (CD) |
Primary outcome
β-hydroxybutyrate
Time frame: 12 weeks
mmol/L
Insulin
Time frame: 12 weeks
IU/mL
Glucose
Time frame: 12 weeks
mg/dL
Omega index
Time frame: 12 weeks
HDL cholesterol
Time frame: 12 weeks
mg/dL
LDL cholesterol
Time frame: 12 weeks
mg/dL
Triacylglycerol
Time frame: 12 weeks
mg/dL
Grelin
Time frame: 12 weeks
ng/mL
cholecystokinin
Time frame: 12 weeks
pg/mL
glucagon-like peptide-1
Time frame: 12 weeks
pg/mL
leptin
Time frame: 12 weeks
ng/mL
peptide YY
Time frame: 12 weeks
pg/mL
gut microbiome
Time frame: 12 weeks
CFU/g
Transcriptomic
Time frame: 12 weeks
log 2fold change
Gene Polymorphism
Time frame: 12 weeks
allel variance
Total cholesterol
Time frame: 12 weeks
mg/dL
HbA1c
Time frame: 12 weeks
Testosterone
Time frame: 12 weeks
nmol/L
Cortisol
Time frame: 12 weeks
μg/dL
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Nutrition
RecruitingPhase 4
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Class I/II Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Active, not recruiting
Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients
Fabry Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Małgorzata Magdalena Michalczyk, Assistante professor contact
Małgorzata M Michalczyk, Assistante professor principal investigator
Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ketogenic Diet (KD) and Vegetarian Diet (VD) in people with Nutrition and Ketogenic Diet, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 2 sites in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Małgorzata Magdalena Michalczyk, Assistante professor (+48535016532, m.michalczyk@awf.katowice.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
β-hydroxybutyrate (time frame: 12 weeks). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.